FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|April 16, 2014
- Melanoma (Issue 2)
- Volume 2
- Issue 1
An Overview of Immune Checkpoint Blockade
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Advertisement
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Read more about immunotherapies and combination strategies for the treatment of melanoma > >
Articles in this issue
over 12 years ago
Sequencing Strategies in Treating Patients With Melanomaover 12 years ago
Research Into Newer Agents Under Way for NRAS Melanomaover 12 years ago
New Crop of Combination Strategies Growing for Melanomaover 12 years ago
In Practice: Combination Therapies in Metastatic Melanomaover 12 years ago
New and Emerging Therapies for Metastatic Melanomaover 12 years ago
Mutation Tests in Melanoma Crucial for Treatmentover 12 years ago
What’s Next With Next-Generation BRAF Inhibitors?Advertisement
Related to this article
A Japanese study found favorable sensitivity and specificity for recurrence of melanoma based on presence of melanoma-specific markers in circulating tumor DNA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
Has CAR T Access Improved 1 Year After REMS Elimination?
5